OUR PIPELINE
A new standard in radiation oncology
Through our lead product NBTXR3, we aim to help millions of patients fighting cancer worldwide by improving treatment outcomes without increasing harmful side effects. We believe that radiotherapy-activated NBTXR3 has the potential to become the global standard of care in the treatment of solid tumors.
NBTXR3 in the clinic
Demonstrated safety, feasibility, and clinical activity of NBTXR3-RT* across multiple solid tumors
NBTXR3-RT*
NBTXR3-RT* + Chemo Tx
NBTXR3-RT* + Chemo Tx
NBTXR3-RT*
Exploring safety, feasibility, and efficacy of NBTXR3-RT* in solid tumors
NBTXR3-RT* + Anti-PD-1
NBTXR3-RT* + Chemo Tx
NBTXR3-RT* + Chemo Tx
NBTXR3-RT*
*NBTXR3-RT: NBTXR3 activated by radiotherapy; **Study terminated prior to completion as result of conclusion of collaboration, results presented at ASCO 22
Clinical trials
Radiotherapy-activated NBTXR3 is currently being evaluated alone and in combination with other anticancer therapies in ongoing clinical trials that span an array of solid tumors. These trials evaluate the efficacy and safety of NBTXR3 in various cancer types and will provide important insights into the potential applications of it in clinical practice.